PROFILPELAJAR.COM

Rifampicin/isoniazid/pyrazinamide
Combination of
Rifampicin	Rifamycin antibiotic
Isoniazid	Anti-tuberculosis medication
Pyrazinamide	Anti-tuberculosis medication
Clinical data
Trade names	Rifater, Trifazid, others
AHFS/Drugs.com	FDA Professional Drug Information
License data	US DailyMed: Rifampin_isoniazid_and_pyrazinamide;
Routes of; administration	By mouth
ATC code	J04AM05 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	161935-14-4;
PubChem CID	6474062;
ChemSpider	none;
KEGG	D10210;
	(verify)

Rifampicin/isoniazid/pyrazinamide, also known as rifampin/isoniazid/pyrazinamide, and sold under the trade name Rifater, is a medication used to treat tuberculosis.^[1] It is a fixed dose combination of rifampicin, isoniazid, and pyrazinamide.^[1] It is used either by itself or along with other antituberculosis medication.^[1] It is taken by mouth.^[1]

Side effects are those of the underlying medications.^[1] These may include poor coordination, loss of appetite, nausea, joint pain, feeling tired, and numbness.^[2] Severe side effects include liver problems.^[3] Use in those under the age of 15 may not be appropriate.^[3] It is unclear if use in pregnancy is safe for the baby.^[3]

Rifampicin/isoniazid/pyrazinamide was approved for medical use in the United States in 1994.^[3] It is on the World Health Organization's List of Essential Medicines.^[4]

Medical uses

The hope of a fixed-dose combination pill is to increase the likelihood that people will take all of three medications.^[5] Also, if people forget to take one or two of their drugs, they might not then develop resistance to the remaining drugs.^{[citation needed]}

Society and culture

It is manufactured by Aventis.^{[citation needed]}

References

^ ^a ^b ^c ^d ^e World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 143. hdl:10665/44053. ISBN 9789241547659.
^ "Rifater Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
^ ^a ^b ^c ^d "Rifater - FDA prescribing information, side effects and uses". www.drugs.com. October 2016. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ Brown MJ, Sharma P, Bennett PN (30 July 2012). Clinical Pharmacology. Elsevier Health Sciences. p. 204. ISBN 978-0-7020-5113-5.